SLC22A2 and acute kidney injury: Although several drugs have been approved clinically as cytoprotective agents for cisplatin-AKI, including OCT2 inhibitors [7] and antioxidant agents [8, 9], all of these drugs are associated with side effects including hypotension and hypocalcemia [10], which may restrict their universal usage for preventing cisplatin-AKI.